dovepress.com
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
It reports real-world effectiveness, safety, treatment persistence, and exploratory drug level (plasma concentration) correlations with endoscopic results, which may help clinicians and patients understand how the drug performs outside trials.
Adults with moderate-to-severe Crohn’s disease, especially those who failed anti-TNF therapy; clinicians treating IBD; and researchers studying JAK inhibitors, drug levels, and biomarkers.
What To Know
What to know This paper reports a retrospective real-world study from a Chinese tertiary center evaluating upadacitinib (a JAK1 inhibitor) in adults with moderate-to-severe Crohn’s disease who failed prior anti-TNF therapy.
The authors collected clinical scores (HBI), endoscopic scores (SES-CD), laboratory markers (CRP, fecal calprotectin, hemoglobin, albumin), treatment persistence, safety events, and measured plasma upadacitinib concentrations to explore associations with endoscopic outcomes.
The study population is anti-TNF refractory and includes patients with complex disease and prior biologic exposure; endoscopy timing and plasma sampling were performed in routine practice (endoscopy often ~6 months, blood 24 hours after a dose).
The report focuses on real-world effectiveness, persistence, safety, and exploratory drug level–outcome relationships in a Chinese cohort. No treatment recommendations are provided in the article text. The findings add real-world data to complement phase 3 trials of upadacitinib and include an Asian population often underrepresented in trials.
Readers should look to the full text for specific outcome measures, sample size, and safety event details.
This is a retrospective, single-center real-world cohort from China; such studies help supplement randomized trial data but have limitations (selection bias, variable follow-up, nonstandardized assessments). Plasma drug concentration analyses are exploratory and do not by themselves establish clinical guidelines or clear exposure-response thresholds.
